CellCentric presents early clinical data at ASH: inobrodib (CCS1477), first in class p300/CBP bromodomain inhibitor treating relapsed refractory multiple myeloma
Retrieved on:
Monday, December 12, 2022
R.J. Corman Railroad Group, Oncology, Hematology, Serum, CBP, Internal medicine, PR, Multiple myeloma, Drug discovery, Society, Endpoint security, Mayo Clinic College of Medicine and Science, Patient, DNA, Mayo Clinic, University of Cambridge, Cancer, Dana–Farber Cancer Institute, Oncogene, Research, Gurdon Institute, Partial-response maximum-likelihood, Takeda Pharmaceutical Company, Division, Disease, NHS foundation trust, MCRPC, Dexamethasone, RRMM, MYC, The Christie NHS Foundation Trust, Lymphatic system, Translation, University, IRF4, University of Manchester, Harvard Medical School, Gene, Toxic leukoencephalopathy, ASH, Cancer research, Medical imaging, Pharmaceutical industry, Medicine
Taken together, these findings provide clear encouragement for the further clinical development of this first in class drug."
Key Points:
- Taken together, these findings provide clear encouragement for the further clinical development of this first in class drug."
- Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational
CellCentric has developed inobrodib from concept through to clinical trials. - It is an oral, first in class small molecule inhibitor drug that targets twin cancer gene regulators p300 and CBP.
- The company actively pursued multiple drug discovery programmes before prioritising p300/CBP inhibition and inobrodib.